Teva Pharma (NYSE: TEVA) announced positive results from a Phase IIb study evaluating the efficacy, safety and tolerability of two ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE